Volume 2, Number 4, December 2001

Prospects for ARB in the next five years
Hicham Skali, Marc A Pfeffer

Based on multiple well-conducted randomised clinical outcome trials (RCT), inhibition of the renin-angiotensin system (RAS) with an angiotensin-converting enzyme inhibitor (ACE-I) has become a firmly established therapeutic approach for reducing morbidity and the risk of death across a broad spectrum of cardiovascular diseases. More recently angiotensin II type 1 (AT₁) receptor blockers (ARBs), another pharmacologic class of agents that inhibits RAS, has become clinically available.
We are fortunately in the midst of an impressive series of RCTs, which collectively will evaluate and quantitate the role of ARBs in clinical practice. Based on the ACE-I experience, we provide a framework to consider the completed and ongoing clinical outcomes RCT with ARBs.

JRAAS 2001;2:215-218.

View full PDF article (open in new window)
Email this article

Right click on this DOI link and copy link to cite this article (What is a DOI link?)